To evaluate and compare the efficacy of newer antidiabetic medications on cardiovascular outcomes
Bibliographic record
Abstract
Millions of individuals worldwide suffer from diabetes mellitus, especially type 2 diabetes (T2D), which significantly increases morbidity and death. Diabetes reduces a person's functioning and quality of life, and because of comor bidities, including cardiovascular (CV) problems, it often leads to early mortality. The study searched for research on the relative effectiveness of more recent antidiabetic drugs on CV outcomes in individuals with T2D mellitus using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The search method comprised medical subject headers and keywords. The RayymanTM tool was used to assess the retrieved articles for eligibility and exclusion criteria. The Newcastle-Ottawa Quality Assessment Scale and the Cochrane risk of bias assessment tool for randomized controlled trials were used to assess the quality and risk of bias. Glucagon-like Peptide-1 (GLP-1) receptor agonists such as liraglutide and semaglutide demonstrated significant cardioprotective effects in high-risk T2D patients. These medications reduced major adverse cardiovascular events and mortality rates compared to traditional therapies. Efpeglenatide and tirzepatide exhibited superior glycemic control and weight reduction benefits, while also improving renal outcomes. However, gastrointestinal side effects were more common, leading to treatment discontinuation in some cases. Newer antidiabetic agents, particularly GLP-1 receptor agonists, offer substantial CV and metabolic benefits for T2D management, especially in high-risk individuals. These medications significantly reduce the risk of CV death and major CV events while improving glycemic control. Future research should prioritize long-term outcomes and safety profiles to enhance therapeutic strategies in diabetes care.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.044 | 0.087 |
| Meta-epidemiology (narrow) | 0.002 | 0.001 |
| Meta-epidemiology (broad) | 0.011 | 0.018 |
| Bibliometrics | 0.004 | 0.004 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.003 | 0.003 |
| Open science | 0.001 | 0.002 |
| Research integrity | 0.003 | 0.002 |
| Insufficient payload (model declined to judge) | 0.008 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".